Next-Generation Synthetic and Biocatalytic Strategies for Therapeutic Oligonucleotide Production: A Process Chemistry Perspective
Organic Process Research & Development · 13.11.2026
DOI: 10.1021/acs.oprd.6c00397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organic Process Research & Development, online erschienen am 13.11.2026. Verfasst von Dnyaneshwar Rasale und 2 weiteren Autor:innen. Die Arbeit nennt 116 Literaturangaben.
Abstract (Originalsprache)
The rapid expansion of oligonucleotide therapeutics has created unprecedented demand for robust, scalable, and economically sustainable manufacturing technologies. While solid-phase phosphoramidite synthesis remains the industry standard for manufacturing antisense oligonucleotides, siRNAs, guide RNAs, aptamers, and other modified oligonucleotides, increasing sequence complexity, extensive chemical modifications, ligand conjugation, sustainability concerns, and manufacturing costs continue to challenge conventional production processes. This review provides a comprehensive process chemistry perspective on next-generation oligonucleotide manufacturing by integrating advances across chemical synthesis, raw material supply, bioconjugation, and emerging biocatalytic technologies. We first review the evolution of phosphoramidite chemistry, including the industrial manufacture of nucleoside phosphoramidites, controlled pore glass and polystyrene supports, synthesis reagents, and modified nucleotide building blocks that underpin commercial oligonucleotide production. The discussion then highlights downstream process development, purification strategies, and manufacturing considerations associated with large-scale oligonucleotide production, followed by recent advances in site-specific bioconjugation with ligands including GalNAc, lipids, peptides, and antibodies that have significantly expanded the extrahepatic delivery of therapeutic oligonucleotide drugs. We emphasize on emerging enzymatic and chemoenzymatic manufacturing platforms, including early ligase-mediated fragment assembly, template-independent terminal deoxynucleotidyl transferase-based controlled enzymatic synthesis, the industrial translation represented by Codexis ECO Synthesis, and the EnPlusOne ezRNA protocols. Finally, we discuss the need for expanding supply chain for modified nucleoside triphosphates, engineered polymerases, ligases, and accessory enzymes. Collectively, these advances demonstrate how the convergence of synthetic chemistry, enzyme engineering, and industrial bioprocess development is reshaping oligonucleotide manufacturing and establishing the foundation for next-generation, cost-effective, and environmentally sustainable production of increasingly complex nucleic acid therapeutics.
Zitieren
APA
Rasale, D., Sanghvi, Y. S., & Kore, A. R. (2026). Next-Generation Synthetic and Biocatalytic Strategies for Therapeutic Oligonucleotide Production: A Process Chemistry Perspective. Organic Process Research & Development. https://doi.org/10.1021/acs.oprd.6c00397
Vancouver
Rasale D, Sanghvi YS, Kore AR. Next-Generation Synthetic and Biocatalytic Strategies for Therapeutic Oligonucleotide Production: A Process Chemistry Perspective. Organic Process Research & Development. 2026. doi:10.1021/acs.oprd.6c00397
BibTeX
@article{Rasale2026,
author = {Rasale, Dnyaneshwar and Sanghvi, Yogesh S. and Kore, Anilkumar R.},
title = {Next-Generation Synthetic and Biocatalytic Strategies for Therapeutic Oligonucleotide Production: A Process Chemistry Perspective},
journal = {Organic Process Research & Development},
year = {2026},
doi = {10.1021/acs.oprd.6c00397}
}
EUVIMED